Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target

Curr Med Chem. 2006;13(17):1971-8. doi: 10.2174/092986706777585013.


The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid beta-peptide. RAGE has a secretory splice isoform, soluble RAGE (sRAGE), that lacks the transmembrane domain and therefore circulates in plasma. By competing with cell-surface RAGE for ligand binding, sRAGE may contribute to the removal/neutralization of circulating ligands thus functioning as a decoy. Clinical studies have recently shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery disease, hypertension, the metabolic syndrome, arthritis and Alzheimer's disease. Increasing the production of plasma sRAGE is therefore considered to be a promising therapeutic target that has the potential to prevent vascular damage and neurodegeneration. This review presents the state of the art in the use of sRAGE as a disease marker and discusses the therapeutic potential of targeting sRAGE for the treatment of inflammation-related diseases such as atherosclerosis, arthritis and Alzheimer's disease.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy
  • Animals
  • Arthritis / diagnosis
  • Arthritis / drug therapy
  • Atherosclerosis / drug therapy
  • Biomarkers / blood
  • Coronary Artery Disease / diagnosis
  • Diabetes Mellitus / diagnosis
  • Drug Design
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Hypertension / diagnosis
  • Inflammation / drug therapy*
  • Ligands
  • Protein Isoforms
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / blood*
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / metabolism*


  • Biomarkers
  • Glycation End Products, Advanced
  • Ligands
  • Protein Isoforms
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic